YaoGeJu

Company directoryChina company filings

Lepu Pharmaceutical Co., Ltd.

As of 20 November 2026, for the company name Lepu Pharmaceutical Co., Ltd. as recorded, 6 applications with this name as first applicant are listed as under review at China's CDE; the CDE acceptance records name it as first applicant on 54 records, across 23 drug names; since 23 August 2026, the records list Accepted: 2 applications, No longer listed under review: 1 application, Supplement delivery: 1 application (NMPA data as of 19 November 2026); the chemical-drug catalogue lists 21 active records with this name as holder; 12 active API registrations list this name as first registered company.

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference

CDE data as of
2026/11/20
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/20.

Drug filings

54 acceptance records as first applicant, grouped into 23 source drug names. Source data as of 2026/11/20.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

度拉糖肽注射液 · No verified English name 2 records · Latest accepted 2026/10/29

New drug · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CXSS2600176New drug2026/10/29Lepu Pharmaceutical Co., Ltd.; Le Pu (Beijing) Bio Technology Co., Ltd. romanizedCDE ↗
CXSS2600175New drug2026/10/29Lepu Pharmaceutical Co., Ltd.; Le Pu (Beijing) Bio Technology Co., Ltd. romanizedCDE ↗
Sacubitril Valsartan Sodium Tablets 2 records · Latest accepted 2026/07/22

Supplement · 1Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2601398Supplement2026/07/22Lepu Pharmaceutical Co., Ltd.CDE ↗
CYHS2303545Generic2023/12/21Lepu Pharmaceutical Co., Ltd.CDE ↗
LPS-001片 · No verified English name 3 records · Latest accepted 2026/02/05

New drug · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CXSL2600173New drug2026/02/05Lepu Pharmaceutical Co., Ltd.CDE ↗
CXSL2600172New drug2026/02/05Lepu Pharmaceutical Co., Ltd.CDE ↗
CXSL2600171New drug2026/02/05Lepu Pharmaceutical Co., Ltd.CDE ↗
KS2308微针贴剂 · No verified English name 2 records · Latest accepted 2025/11/27

New drug · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CXSL2501015New drug2025/11/27Lepu Pharmaceutical Co., Ltd.CDE ↗
CXSL2501014New drug2025/11/27Lepu Pharmaceutical Co., Ltd.CDE ↗
卡格列净二甲双胍缓释片 · No verified English name 6 records · Latest accepted 2025/08/19

Generic · 6

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2503040Generic2025/08/19Lepu Pharmaceutical Co., Ltd.CDE ↗
CYHS2503039Generic2025/08/19Lepu Pharmaceutical Co., Ltd.CDE ↗
CYHS2503038Generic2025/08/19Lepu Pharmaceutical Co., Ltd.CDE ↗
CYHS2503037Generic2025/08/19Lepu Pharmaceutical Co., Ltd.CDE ↗
CYHS2201146Generic2022/07/27Lepu Pharmaceutical Co., Ltd.CDE ↗
CYHS2102070Generic2021/11/23Lepu Pharmaceutical Co., Ltd.CDE ↗
Diquafosol Sodium Eye Drops 2 records · Latest accepted 2024/11/28

Supplement · 1Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2402001Supplement2024/11/28Lepu Pharmaceutical Co., Ltd.CDE ↗
CYHS2301822Generic2023/07/07Lepu Pharmaceutical Co., Ltd.CDE ↗
Sodium Hyaluronate Eye Drops 3 records · Latest accepted 2024/10/09

Generic · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2403339Generic2024/10/09Lepu Pharmaceutical Co., Ltd.CDE ↗
CYHS2403338Generic2024/10/09Lepu Pharmaceutical Co., Ltd.CDE ↗
CYHS2302551Generic2023/09/21Lepu Pharmaceutical Co., Ltd.CDE ↗
Sildenafil Citrate Tablets 2 records · Latest accepted 2024/07/04

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2402006Generic2024/07/04Lepu Pharmaceutical Co., Ltd.CDE ↗
CYHS2402005Generic2024/07/04Lepu Pharmaceutical Co., Ltd.CDE ↗
LPS-001注射液 · No verified English name 1 records · Latest accepted 2024/04/16

New drug · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CXSL2400231New drug2024/04/16Lepu Pharmaceutical Co., Ltd.CDE ↗
Metformin Hydrochloride And Empagliflozin Extended Release Tablets 5 records · Latest accepted 2024/02/20

Generic · 5

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2400624Generic2024/02/20Lepu Pharmaceutical Co., Ltd.CDE ↗
CYHS2400623Generic2024/02/20Lepu Pharmaceutical Co., Ltd.CDE ↗
CYHS2400622Generic2024/02/20Lepu Pharmaceutical Co., Ltd.CDE ↗
CYHS2300066Generic2023/01/09Lepu Pharmaceutical Co., Ltd.CDE ↗
CYHS2300065Generic2023/01/09Lepu Pharmaceutical Co., Ltd.CDE ↗
硫酸阿托品滴眼液 · No verified English name 8 records · Latest accepted 2023/12/27

New drug · 8

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CXHL2301450New drug2023/12/27Lepu Pharmaceutical Co., Ltd.CDE ↗
CXHL2301449New drug2023/12/27Lepu Pharmaceutical Co., Ltd.CDE ↗
CXHL2301262New drug2023/11/11Lepu Pharmaceutical Co., Ltd.CDE ↗
CXHL2301261New drug2023/11/11Lepu Pharmaceutical Co., Ltd.CDE ↗
CXHL2300822New drug2023/07/28Lepu Pharmaceutical Co., Ltd.CDE ↗
CXHL2300821New drug2023/07/28Lepu Pharmaceutical Co., Ltd.CDE ↗
CXHL2200363New drug2022/06/09Lepu Pharmaceutical Co., Ltd.CDE ↗
CXHL2200362New drug2022/06/09Lepu Pharmaceutical Co., Ltd.CDE ↗
Moxifloxacin Hydrochloride Eye Drops 1 records · Latest accepted 2023/03/28

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2300920Generic2023/03/28Lepu Pharmaceutical Co., Ltd.CDE ↗
Esomeprazole Magnesium Enteric-Coated Capsules 2 records · Latest accepted 2022/11/01

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2201868Generic2022/11/01Lepu Pharmaceutical Co., Ltd.CDE ↗
CYHS2201867Generic2022/11/01Lepu Pharmaceutical Co., Ltd.CDE ↗
注射用头孢哌酮钠他唑巴坦钠 · No verified English name 2 records · Latest accepted 2022/10/21

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2201944Supplement2022/10/21Lepu Pharmaceutical Co., Ltd.CDE ↗
CYHB2201943Supplement2022/10/21Lepu Pharmaceutical Co., Ltd.CDE ↗
Compound Glycyrrhizin Tablets 1 records · Latest accepted 2022/05/06

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2250261Supplement2022/05/06Lepu Pharmaceutical Co., Ltd.CDE ↗
Cefoperazone Sodium and Sulbactam Sodium for Injection 3 records · Latest accepted 2022/04/29

Supplement · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2250256Supplement2022/04/29Lepu Pharmaceutical Co., Ltd.CDE ↗
CYHB2250255Supplement2022/04/29Lepu Pharmaceutical Co., Ltd.CDE ↗
CYHB2250254Supplement2022/04/29Lepu Pharmaceutical Co., Ltd.CDE ↗
Nifedipine Controlled-release Tablets 1 records · Latest accepted 2022/04/27

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2200663Generic2022/04/27Lepu Pharmaceutical Co., Ltd.CDE ↗
Esomeprazole Sodium for Injection 1 records · Latest accepted 2021/12/28

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2151120Supplement2021/12/28Lepu Pharmaceutical Co., Ltd.CDE ↗
Lansoprazole For Injection 1 records · Latest accepted 2021/12/16

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2151095Supplement2021/12/16Lepu Pharmaceutical Co., Ltd.CDE ↗
Empagliflozin Tablets 2 records · Latest accepted 2021/10/19

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2101879Generic2021/10/19Lepu Pharmaceutical Co., Ltd.CDE ↗
CYHS2101878Generic2021/10/19Lepu Pharmaceutical Co., Ltd.CDE ↗
替格瑞洛阿司匹林胶囊 · No verified English name 1 records · Latest accepted 2021/09/17

New drug · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CXHL2101487New drug2021/09/17Lepu Pharmaceutical Co., Ltd.CDE ↗
Rivaroxaban Tablets 2 records · Latest accepted 2021/08/16

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2101587Generic2021/08/16Lepu Pharmaceutical Co., Ltd.; Le Pu Pharma Shareholding You Company romanizedCDE ↗
CYHS2101586Generic2021/08/16Lepu Pharmaceutical Co., Ltd.; Le Pu Pharma Shareholding You Company romanizedCDE ↗
硫酸氢氯吡格雷阿司匹林片 · No verified English name 1 records · Latest accepted 2021/07/08

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2101422Generic2021/07/08Lepu Pharmaceutical Co., Ltd.CDE ↗

Changes in the last 90 days

4 events from 2026/08/23 to 2026/11/20. CDE data as of 2026/11/20; NMPA data as of 2026/11/19.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

Accepted: 2 applicationsNo longer listed under review: 1 applicationSupplement delivery: 1 application

  1. 2026/11/07No longer listed under review

    Sacubitril Valsartan Sodium Tablets

    CYHB2601398

    Fact date: 2026/11/07 · Date added to this site: 2026/11/07

    Accepted: 2026/07/22

    no longer on the CDE under-review list as of the data cut-off; NMPA published approval-document delivery for this acceptance number on 2026/11/06 (approval no.: —; approval date: 2026/11/05); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 21

    NMPA · Table row 21 ↗ View source ↗
  2. 2026/11/05Supplement delivery

    Sacubitril Valsartan Sodium Tablets

    CYHB2601398

    Fact date: 2026/11/05 · Publication date: 2026/11/06 · Date added to this site: 2026/11/06

    Supplemental application; excluded from new marketing approvals.

    View source · Table row 21 ↗
  3. 2026/10/29Accepted

    度拉糖肽注射液 · No verified English name

    CXSS2600176

    Fact date: 2026/10/29 · Date added to this site: 2026/10/30

    View source ↗
  4. 2026/10/29Accepted

    度拉糖肽注射液 · No verified English name

    CXSS2600175

    Fact date: 2026/10/29 · Date added to this site: 2026/10/30

    View source ↗

Under review

6 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/20.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
度拉糖肽注射液 · No verified English name CXSS2600176New drug2026/10/29Lepu Pharmaceutical Co., Ltd.; Le Pu (Beijing) Bio Technology Co., Ltd. romanizedCDE ↗
度拉糖肽注射液 · No verified English name CXSS2600175New drug2026/10/29Lepu Pharmaceutical Co., Ltd.; Le Pu (Beijing) Bio Technology Co., Ltd. romanizedCDE ↗
卡格列净二甲双胍缓释片 · No verified English name CYHS2503040Generic2025/08/19Lepu Pharmaceutical Co., Ltd.CDE ↗
卡格列净二甲双胍缓释片 · No verified English name CYHS2503039Generic2025/08/19Lepu Pharmaceutical Co., Ltd.CDE ↗
卡格列净二甲双胍缓释片 · No verified English name CYHS2503038Generic2025/08/19Lepu Pharmaceutical Co., Ltd.CDE ↗
卡格列净二甲双胍缓释片 · No verified English name CYHS2503037Generic2025/08/19Lepu Pharmaceutical Co., Ltd.CDE ↗

Catalogue holder records

21 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/20. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerNMPA approval no.ApprovedCatalogue category (source text)View source
Sildenafil Citrate TabletsLepu Pharmaceutical Co., Ltd.Lepu Pharmaceutical Co., Ltd.国药准字H202637172026/03/25Generic approved under the new chemical-drug registration classificationCDE ↗
Sildenafil Citrate TabletsLepu Pharmaceutical Co., Ltd.Lepu Pharmaceutical Co., Ltd.国药准字H202637182026/03/25Generic approved under the new chemical-drug registration classificationCDE ↗
恩格列净二甲双胍缓释片(II) · No verified English nameLepu Pharmaceutical Co., Ltd.Lepu Pharmaceutical Co., Ltd.国药准字H202633232026/02/02Generic approved under the new chemical-drug registration classificationCDE ↗
恩格列净二甲双胍缓释片(III) · No verified English nameLepu Pharmaceutical Co., Ltd.Lepu Pharmaceutical Co., Ltd.国药准字H202633242026/02/02Generic approved under the new chemical-drug registration classificationCDE ↗
恩格列净二甲双胍缓释片(I) · No verified English nameLepu Pharmaceutical Co., Ltd.Lepu Pharmaceutical Co., Ltd.国药准字H202633222026/02/02Generic approved under the new chemical-drug registration classificationCDE ↗
Sacubitril Valsartan Sodium TabletsLepu Pharmaceutical Co., Ltd.Lepu Pharmaceutical Co., Ltd.国药准字H202540292025/04/30Generic approved under the new chemical-drug registration classificationCDE ↗
Esomeprazole Magnesium Enteric-Coated CapsulesLepu Pharmaceutical Co., Ltd.Lepu Pharmaceutical Co., Ltd.国药准字H202443242024/06/28Generic approved under the new chemical-drug registration classificationCDE ↗
Esomeprazole Magnesium Enteric-Coated CapsulesLepu Pharmaceutical Co., Ltd.Lepu Pharmaceutical Co., Ltd.国药准字H202443252024/06/24Generic approved under the new chemical-drug registration classificationCDE ↗
Cefoperazone Sodium and Sulbactam Sodium for InjectionLepu Pharmaceutical Co., Ltd.Lepu Pharmaceutical Co., Ltd.国药准字H200230982023/12/28Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Cefoperazone Sodium and Sulbactam Sodium for InjectionLepu Pharmaceutical Co., Ltd.Lepu Pharmaceutical Co., Ltd.国药准字H200230992023/12/28Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Compound Glycyrrhizin TabletsLepu Pharmaceutical Co., Ltd.Lepu Pharmaceutical Co., Ltd.国药准字H200737232023/12/19Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Nifedipine Controlled-release TabletsLepu Pharmaceutical Co., Ltd.Lepu Pharmaceutical Co., Ltd.国药准字H202345062023/11/21Generic approved under the new chemical-drug registration classificationCDE ↗
Empagliflozin TabletsLepu Pharmaceutical Co., Ltd.Lepu Pharmaceutical Co., Ltd.国药准字H202338942023/06/30Generic approved under the new chemical-drug registration classificationCDE ↗
Lansoprazole For InjectionLepu Pharmaceutical Co., Ltd.Lepu Pharmaceutical Co., Ltd.国药准字H202031492023/05/31Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Esomeprazole Sodium for InjectionLepu Pharmaceutical Co., Ltd.Lepu Pharmaceutical Co., Ltd.国药准字H202031272023/03/21Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Clopidogrel Bisulfate and Aspirin TabletsLepu Pharmaceutical Co., Ltd.Lepu Pharmaceutical Co., Ltd.国药准字H202238432022/11/15Generic approved under the new chemical-drug registration classificationCDE ↗
Rivaroxaban TabletsLepu Pharmaceutical Co., Ltd.Lepu Pharmaceutical Co., Ltd.国药准字H202238612022/11/15Generic approved under the new chemical-drug registration classificationCDE ↗
Apixaban TabletsLepu Pharmaceutical Co., Ltd.Lepu Pharmaceutical Co., Ltd.国药准字H202139372021/12/14Generic approved under the new chemical-drug registration classificationCDE ↗
Ticagrelor TabletsLepu Pharmaceutical Co., Ltd.Lepu Pharmaceutical Co., Ltd.国药准字H202131672021/03/09Generic approved under the new chemical-drug registration classificationCDE ↗
Ticagrelor TabletsLepu Pharmaceutical Co., Ltd.Lepu Pharmaceutical Co., Ltd.国药准字H202131682021/03/09Generic approved under the new chemical-drug registration classificationCDE ↗
Isosorbide Mononitrate Extended-Release TabletsLepu Pharmaceutical Co., Ltd.Lepu Pharmaceutical Co., Ltd.国药准字H200662032021/02/09Drug that passed quality-and-efficacy consistency evaluationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

12 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/20.

NameCompany / applicantRegistration numberStatusSource update dateView source
卡格列净 · No verified English nameLepu Pharmaceutical Co., Ltd.Y20230001275A2025/06/23CDE ↗
恩格列净 · No verified English nameLepu Pharmaceutical Co., Ltd.Y20210000790A2024/01/17CDE ↗
甲磺酸仑伐替尼 · No verified English nameLepu Pharmaceutical Co., Ltd.Y20210000391A2023/08/10CDE ↗
阿哌沙班 · No verified English nameLepu Pharmaceutical Co., Ltd.Y20200000491A2026/10/12CDE ↗
兰索拉唑 · No verified English nameLepu Pharmaceutical Co., Ltd.Y20190007737A2024/09/11CDE ↗
帕马溴 · No verified English nameLepu Pharmaceutical Co., Ltd.Y20190007259A—CDE ↗
伊曲康唑 · No verified English nameLepu Pharmaceutical Co., Ltd.Y20190007019A—CDE ↗
盐酸甲砜霉素甘氨酸酯 · No verified English nameLepu Pharmaceutical Co., Ltd.Y20190003999A2024/09/11CDE ↗
盐酸文拉法辛 · No verified English nameLepu Pharmaceutical Co., Ltd.Y20190003998A2024/12/19CDE ↗
富马酸替诺福韦二吡呋酯 · No verified English nameLepu Pharmaceutical Co., Ltd.Y20170001084A2024/09/11CDE ↗
枸橼酸西地那非 · No verified English nameLepu Pharmaceutical Co., Ltd.Y20170000614I—CDE ↗
艾司奥美拉唑钠 · No verified English nameLepu Pharmaceutical Co., Ltd.Y20170000384A2024/10/10CDE ↗

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/20.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/20
Chemical-drug catalogue
Last successful update: 2026/11/20
API registrations
Last successful update: 2026/11/20
NMPA drug delivery notices
Last successful update: 2026/11/19

Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.